Administrative Core

行政核心

• 批准号: 10005118
• 负责人: Kevin D Cooper
• 金额: $ 33.34万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-20 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005118
• 关键词: Accountability; Achievement; Advisory Committees; Area; Artificial Intelligence; Bioinformatics; Clinical Data; Clinical Research; Communities; Computational algorithm; Computerized Medical Record; Core Facility; Cutaneous; Data; Data Set; Databases; Dermatology; Development; Electronic Health Record; Environment; Goals; Health Care Research; Healthcare; Healthcare Systems; Hospitals; Human; Human Experimentation; Infrastructure; Leadership; Machine Learning; Medical center; Methodology; Mission; Modeling; Mus; Pathway interactions; Patients; Pharmaceutical Preparations; Pre-Clinical Model; Process; Provider; Psoriasis; Research; Research Personnel; Research Project Grants; Resources; Role; Scientist; System; Talents; Techniques; Technology; Testing; Translating; Translational Research; University Hospitals; Unmarried person; Validation; Work; clinical application; clinical phenotype; cohort; comorbidity; data mining; decision making algorithm; design; experience; individual patient; innovation; innovative technologies; new technology; novel; programs; recruit; symposium

The mission of the CORT is to advance therapy for psoriasis and related comorbidities by leveraging new bioinformatic methodologies with well-developed murine and human experimentation capabilities. This technology concatenation is expected to more nimbly translate new scientific opportunities into clinical applications. The CORT Administrative Core (AC) proposes to manage an innovative model wherein a collaborative research project (CRP) will serve as the central hub that will iterate significant bi-directional work from 2 highly interactive research cores to experimentally test hypotheses and newly identified pathway specific and repurposed FDA drug leads. The AC will accomplish this goal through its Aims to: 1. Convene an Internal Advisory Committee and an External Advisory Board which a) develops and applies accountability metrics for the CRP, each Core, and the P&F projects, b) manages a Go-NoGo iterative algorithmic decision-making process regarding CORT resource utilization and c) coordinates patient cohort assets and regulatory compliance; 2. Provide fiscal management of the CORT; 3. Branch out exciting new developments deriving from CORT findings through a robust Pilot & Feasibility (P&F) program; 4. Organize and advertise Enrichment Activities that bring CORT and Community researchers together in scientific venues to exchange ideas and new technologies. The AC leadership will work closely not only with lab scientists, but also with the leadership and programmers of the CLEveland Area Research Platform for Advancing Translational Healthcare (CLEARPATH), a comprehensive research database with Limited Data Set contribution from all 3 major Cleveland healthcare systems. CLEARPATH will create connected data (e.g., Biospecimen results, EMR clinical phenotype, `Omics data) as well as a Single person record across the system, enabling research cohort discovery and validation across the aggregate dataset. This approach will allow us to preliminarily validate psoriasis cohort subsets, mix `omic pathways and drug leads identified by the Cores and CRP. In addition to its roles as an information conduit and facilitator for research, the AC also promotes the cutaneous research environment for psoriasis and its comorbid and related conditions through enrichment programs. As such, the AC is instrumental in the design and planning of research symposia, and recruiting potential P&F program recipients with innovative technologies and/or complementary research expertise to the CORT. The cross-disciplinary approach of combining a Preclinical Modeling Core (PMC) with an Applied Meta `Omics Core (AMC) that takes advantage of artificial intelligence, data mining, network techniques and machine learning to query available interaction networks and highly annotated integrated electronic medical records (EMRi) is highly innovative. The active engagement of the AC will be instrumental for the successful achievement of the broader goal of identifying new psoriasis pathways and repurposed approved drugs.

科特的任务是通过利用新的新的牛皮癣和相关合并症来提高治疗 具有良好发达的鼠和人类实验能力的生物信息学方法论。这 技术串联有望更灵活地将新的科学机会转化为临床 申请。 Cort行政核心（AC）提议管理一个创新模型，其中 协作研究项目（CRP）将作为中央枢纽，将迭代重要的双向 从2个高度互动研究核心到实验检验假设和新鉴定的工作 途径特定和重新利用的FDA药物铅。 AC将通过其目标来实现这一目标：1。 召集内部咨询委员会和外部顾问委员会，该委员会a）开发和申请 CRP的问责制指标，每个核心和P＆F项目，b）管理一个迭代 有关Cort资源利用和c）协调患者队列的算法决策过程 资产和法规合规性； 2。提供Cort的财政管理； 3.分支令人兴奋的新 通过强大的飞行员和可行性（P＆F）计划衍生出Cort发现的发展； 4。组织 并宣传丰富的活动，使科特和社区研究人员在科学场所聚集在一起 交换思想和新技术。 AC领导不仅将与实验室科学家紧密合作，而且还将与领导和 克利夫兰地区研究平台的程序员，用于推进转化医疗保健 （ClearPath），这是一个全面的研究数据库，具有有限的数据集贡献 克利夫兰医疗保健系统。 ClearPath将创建连接的数据（例如，BioSseCemen结果，EMR 临床表型，“ OMICS数据）以及整个系统中的单一人物记录，使研究队列能够 整个数据集的发现和验证。这种方法将使我们能够初步验证 牛皮癣队列亚群，混合``OMIC途径''和CRP鉴定的药物铅。此外 AC还作为信息管道和研究的促进者的作用，还促进了皮肤研究 牛皮癣的环境及其合并症及相关条件通过富集计划。因此， AC在研究研讨会的设计和计划中发挥了作用，并招募了潜在的P＆F计划 具有创新技术和/或Cort的补充研究专业知识的接受者。 将临床前建模核心（PMC）与施加的meta相结合的跨学科方法 `使用人工智能，数据挖掘，网络技术和 机器学习查询可用的交互网络和高度注释的集成电子医疗 记录（EMRI）具有很高的创新性。 AC的积极参与将有助于成功 实现确定新的牛皮癣途径并重新利用的批准药物的更广泛目标。